Go Deep
Vir Biotechnology, Inc.
Vir Biotechnology, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,297 | -6.6 | 2.02 | 0.10 | 1,130.08 |
| Oct 2026 | 18,433 | -6.4 | 1.95 | 0.10 | 1,081.87 |
| Oct 2026 | 18,827 | -6.0 | 1.83 | 0.10 | 1,010.43 |
| Oct 2026 | 18,928 | -5.9 | 1.79 | 0.10 | 988.40 |
| Oct 2026 | 18,898 | -6.1 | 1.80 | 0.10 | 994.24 |
| Oct 2026 | 19,155 | -5.7 | 1.72 | 0.10 | 943.36 |
| Oct 2026 | 19,029 | -5.8 | 1.76 | 0.10 | 968.08 |
| Oct 2026 | 18,762 | -6.1 | 1.85 | 0.10 | 1,018.33 |
| Oct 2026 | 18,848 | -6.0 | 1.82 | 0.10 | 999.73 |
| Oct 2026 | 18,918 | -5.9 | 1.80 | 0.10 | 984.50 |
Vir Biotechnology, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 238,935,000.0 | -41,000.0 | 63,760,000.0 | -65,000.0 |
| Net Profit | 80,080,000.0 | -125,695,000.0 | -42,923,000.0 | -163,141,000.0 |
| EPS | 0.5 | -0.8 | -0.3 | -1.2 |
Vir Biotechnology, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 66,520,000.0 | 63,712,000.0 | 39,494,000.0 | 1,580,472,000.0 |
| Net Profit | -437,987,000.0 | -521,960,000.0 | -615,061,000.0 | 515,837,000.0 |
| EPS | -3.2 | -3.8 | -4.6 | 3.9 |
Vir Biotechnology, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,002,823,000.0 | 1,398,813,000.0 | 1,919,060,000.0 | 2,802,088,000.0 | — |
| Total Liabilities | 237,547,000.0 | 248,428,000.0 | 328,824,000.0 | 724,125,000.0 | — |
| Total Equity | 765,276,000.0 | 1,150,385,000.0 | 1,590,236,000.0 | 2,077,963,000.0 | — |
Owes vs Owns
Vir Biotechnology, Inc. owed $0.19 for every $1 it owned in Jun 2026, down from $0.26 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.19× | 0.24× | 0.18× | 0.17× | 0.26× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Vir Biotechnology, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 46.6%Fixed assets (tangible) 11.7%Intangible assets 2.5%Long-term investments 31.4%Other assets 7.9%
How it's funded — Dec 2025
Short-term debt 0.9%Long-term debt 8.9%Payables 1.0%Other liabilities 13.0%Shareholders' equity 76.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 467.0 | 905.3 | 1,522.4 | 2,402.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 117.7 | 122.9 | 167.2 | 188.2 |
| Intangible assets | 24.8 | 25.1 | 39.5 | 49.7 |
| Long-term investments | 314.6 | 190.0 | 105.3 | 23.9 |
| Other assets | 78.7 | 155.5 | 84.6 | 138.3 |
| Liabilities & equity | ||||
| Short-term debt | 8.8 | 7.8 | 12.9 | 4.1 |
| Long-term debt | 89.1 | 90.1 | 111.7 | 123.8 |
| Payables | 9.8 | 5.1 | 6.3 | 6.4 |
| Other liabilities | 129.9 | 145.5 | 197.9 | 589.7 |
| Shareholders' equity | 765.3 | 1,150.4 | 1,590.2 | 2,078.0 |
| Net tangible assets | 740.5 | 1,125.3 | 1,550.7 | 2,028.3 |
Vir Biotechnology, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -391,781,000.0 | -446,352,000.0 | -778,785,000.0 | 1,663,253,000.0 | — |
| Investing Activities | 310,371,000.0 | 499,367,000.0 | 164,629,000.0 | -1,193,461,000.0 | — |
| Financing Activities | 3,785,000.0 | 4,388,000.0 | 7,480,000.0 | 34,761,000.0 | — |